Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biochemical response of PBC–AIH overlap syndrome induced by ursodeoxycholic acid only or combination therapy of immunosuppressive agents
ChiCTR-IPR-16008935Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jan 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ursodeoxycholic acid in autoimmune hepatitis-primary biliary cholangitis overlap syndrome (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Biochemical response rate. Started Jan 2014; status: recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
autoimmune hepatitis-primary biliary cholangitis overlap syndrome
Beyond the preview
Go deeper on ChiCTR-IPR-16008935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008935.